Quest Diagnostics (DGX) EBIAT: 2009-2025
Historic EBIAT for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to $259.0 million.
- Quest Diagnostics' EBIAT rose 9.28% to $259.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 15.28%. This contributed to the annual value of $921.0 million for FY2024, which is 1.43% up from last year.
- According to the latest figures from Q3 2025, Quest Diagnostics' EBIAT is $259.0 million, which was down 12.50% from $296.0 million recorded in Q2 2025.
- In the past 5 years, Quest Diagnostics' EBIAT ranged from a high of $650.0 million in Q2 2021 and a low of $116.0 million during Q4 2022.
- Its 3-year average for EBIAT is $238.1 million, with a median of $237.0 million in 2024.
- Per our database at Business Quant, Quest Diagnostics' EBIAT soared by 362.26% in 2021 and then crashed by 71.91% in 2022.
- Over the past 5 years, Quest Diagnostics' EBIAT (Quarterly) stood at $413.0 million in 2021, then tumbled by 71.91% to $116.0 million in 2022, then surged by 76.72% to $205.0 million in 2023, then rose by 15.12% to $236.0 million in 2024, then increased by 9.28% to $259.0 million in 2025.
- Its EBIAT was $259.0 million in Q3 2025, compared to $296.0 million in Q2 2025 and $235.0 million in Q1 2025.